Pelage’s PP405, a first-in-class regenerative treatment, reactivates dormant stem cells to regrow hair. Phase 2a shows early, significant results.

Nelnet (NYSE: NNI) today reported GAAP net income of $181.5 million, or $4.97 per share, for the second quarter of 2025, compared with GAAP net income of $45.1 million, or $1.23 per share, for the ...

DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated ...

Testosterone replacement therapy (TRT) is a common treatment for easing symptoms of low testosterone (hypogonadism) in men.